Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
“(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell announced on Friday that the enrolment and treatment of the first patient had taken place in its multicentre phase 2 clinical trial of its 'SCIB1' tumour treatment at the Churchill Hospital in Oxford.
The AIM-traded firm said the phase 2 study was designed to assess whether the addition of SCIB1 to pembrolizumab, known by the trade name Keytruda, would result in an improvement in the tumour response rate, progression-free survival and overall survival in patients with advanced melanoma.
As a result of the Covid-19 pandemic, screening and recruitment into the study was paused due to the prioritisation of coronavirus patients in UK hospitals.
Patient screening had now been re-initiated across the UK, however, with Poulam Patel, professor of clinical oncology at the University of Nottingham, acting as chief investigator.
The company said the Nottingham site, along with the Oxford centre, Velindre Hospital and Mount Vernon Hospital, were actively screening subjects, with additional centres due to join them in the coming months.
Scancell said SCIB1 is the lead product from its 'ImmunoBody' immunotherapy platform, which uses the body's immune system to identify, attack and destroy tumours.
That, it said, was achieved by delivering a DNA plasmid using Ichor's 'TriGrid 2.0' electroporation delivery device, to enhance the uptake and presentation of cancer antigens to harness high-avidity T-cell responses.
In a phase 1 and 2 clinical trial, survival following SCIB1 monotherapy was superior to historical survival rates, with 14 of 16 resected patients surviving for more than five years.
Although pembrolizumab is an approved therapy for advanced melanoma, response to treatment was limited to only around 30% of patients.
The company said the phase 2 study was designed to assess whether the addition of SCIB1 treatment to pembrolizumab would result in an improvement in patient outcomes.
"We are delighted to have started our SCIB1 phase 2 trial in the UK as we believe that SCIB1 administration in combination with an immune checkpoint inhibitor such as pembrolizumab has the potential to offer greater efficacy than when either agent is used alone," said chief executive officer Lindy Durrant.
At 1303 GMT, shares in Scancell Holdings were up 1.1% at 20.22p.”
Would it be unreasonable to expect an update after 6 months on this FPD
Short signal was issued on 11/05/2022 when the stock price was 14.13 since then Scancell has fallen by -12.92%This now looks hopefully to be running out of steam However these types of attack are very damaging for companies like Scancell which just take these cruel hits which are nonsensical
Rant over
Now would be a good time to do an update ie proactive interview. This would update the huge amount of progress Scancell have made prior to a formal RSN in June ( end H1 22 ) with the possible positive effect which may stop the share price slide and encourage fresh interests. Let’s start with a rising share price prior to the barrage of RNS’s
Sooooooon
Best ever RNS we look as if everything we could have ever imagined had arrived
The positive transition and expansion of multiple clinical trials give Scancell not only the opportunity to achieve but exceed more than we could ask for
As a long term holder for over 8 years mainly losing money.
I feel this is RG’s pivotal year we have all been waiting for
Good luck to all LTH and most importantly a “potential cure for cancer “
https://www.aljazeera.com/news/2022/2/18/six-african--to-kick-production-of-mrna-vaccines
I think we have been out manoeuvred by European politicians, the promises to the SA government with all the usual incentives which in the short term appeals to keeping them in office and giving the chance to shine taking a full part in there own destiny even though these short lived shots won’t deliver the best outcome for a nation which need to be focussed on a second generation vaccine which has a broad spectrum immunity and enhanced longevity with easy storage and delivery
Come on Scancell work some magic for the sake of Africa and a better worlds solution.IMO
Stock shooters now closing position until next time when the shares rise sufficiently
Short and buy back
Interesting article
Variant VaccineWed 17:29
https://www.defenseone.com/technology/2021/12/us-army-creates-single-vaccine-effective-against-all-covid-sars-variants/360089/
C7 always happy to support BJ and our gov
However, The way the UK airports are not geared to test passengers on flights from SA is unacceptable
It’s OK to draw attention to matters reported in the papers thanks to TF
Come on Scancell time is of the essence. Sooon is good “prove it or loose it”
Crumbs
Always love your post, and keeps me believing after so many years we will be successful
Maybe they should get some tips from Oxford Vacmedix how to progress a little quicker into trial as it seem our Achilles heal
As you posted
“Ms Hick, a former intensive care nurse, who was diagnosed with ovarian cancer in 2012, has been told the new vaccine is now the only treatment available to her as all others have failed to work.'
https://toysmatrix.com/cancer-vaccine-breakthrough-terminally-ill-patients-in-new-trial-could-change-landscape/“
Take care all